Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, March 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ODDITY Tech Ltd....
-
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Oddity Tech Ltd. (“Oddity” or the "Company") (NASDAQ:ODD) investors of a class action on behalf of investors that bought...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Oddity (ODD) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Oddity To Contact Him Directly To Discuss Their Options If you purchased or...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ODDITY (NASDAQ: ODD) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Robbins Geller is investigating potential violations of U.S. federal securities laws involving Oddity.
-
In a digital world where algorithms grow more powerful by the day, Sidetrade, a pioneer in AI-powered cash flow management, reaffirms its role as a responsible leader. Today, the company releases its...
-
Dans un monde numérique où les algorithmes gagnent chaque jour en puissance, Sidetrade, pionnier de l’intelligence artificielle (IA) au service de la gestion du cashflow des entreprises, réaffirme sa...
-
ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy...
-
FDA grants Orphan Drug Designation to Medicovestor’s ADoBind MC001, a novel ADC targeting hard-to-treat pancreatic cancer.